Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Medical weight loss is most successful when treatment, lifestyle change and expert supervision work together not in isolation
Pcos and inositolsadvances and lessons we are learning
Let us show you why our approach stands out from the crowd
The gut barrier is supposed to keep potentially inflammatory proteins from entering our bloodstream, where they can trigger an immune response, even contributing to autoimmunity
This is about saving hearts Who qualifies: Adults with established CVD + overweight/obesity (BMI 27 kg/m) The drug: Semaglutide 2.4mg once-weekly subcutaneous injection (GLP-1 RA) Titrated to maintenance dose Adjunct to lifestyle counselling & standard care Why NICE said yes: Reduces risk of MACE (heart attack, stroke, CV death) in this population Cost-effective within NHS thresholds (20,00030,000/QALY) Commercial agreement already in place with NHS The pathway is simple: Assess CVD risk Lifestyle counselling Add semaglutide Monitor This follows SELECT trial data showing ~20% MACE reduction independent of weight loss We are watching GLP-1s redefine cardiovascular medicine in real time From diabetes obesity now primary CV risk reduction Whats next
Q: When is it recommended to use this product
US$ 24.85
US$ 29.96
US$ 29.48
US$ 21.38
US$ 26.65
US$ 23.40
US$ 26.73
US$ 20.96
